Abiopharma

🔍 BENDHEIM JACK (Director)

Company: PHIBRO ANIMAL HEALTH CORP (PAHC)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Sold 2,757 shares of Class A Common Stock at $40.6096 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 42,195.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 2,995 shares of Class A Common Stock at $41.2167 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 39,200.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2025-12-11 | Code: H | shares_owned_after: 16,840.00 | Footnotes: F5

Footnotes:

• F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $41.025. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.
• F3: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.095 to $41.38.
• F5: The reported securities are directly held by Jack Bendheim.